CL2017001375A1 - Métodos de monitoreo terapéutico de profármacos de ácido fenilacético. - Google Patents
Métodos de monitoreo terapéutico de profármacos de ácido fenilacético.Info
- Publication number
- CL2017001375A1 CL2017001375A1 CL2017001375A CL2017001375A CL2017001375A1 CL 2017001375 A1 CL2017001375 A1 CL 2017001375A1 CL 2017001375 A CL2017001375 A CL 2017001375A CL 2017001375 A CL2017001375 A CL 2017001375A CL 2017001375 A1 CL2017001375 A1 CL 2017001375A1
- Authority
- CL
- Chile
- Prior art keywords
- faa
- hpn
- prodrugs
- methods
- phenylacetic acid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6806—Determination of free amino acids
- G01N33/6812—Assays for specific amino acids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Emergency Medicine (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Pain & Pain Management (AREA)
Abstract
<p>LA PRESENTE INVENCIÓN SE REFIERE AL USA DE GLICERIL TRI-[4-FENILBUTIRATO] (HPN-100), PARA PREPARAR UN MEDICAMENTO ÚTIL PARA TRATAR UNA CONDICIÓN SELECCIONADA A PARTIR DEL GRUPO QUE CONSISTE DE CÁNCER, UNA ENFERMEDAD NEURODEGENERATIVAS, UN TRASTORNO METABÓLICO, Y ENFERMEDAD DE CÉLULAS FALCIFORMES PARA LA CUAL EL USO DE GLICERIL TRI-[4-FENILBUTIRATO] (HPN-100) SE ESPERA SEA BENÉFICA EN UN SUJETO, QUE POSEE UNA RELACIÓN EN PLASMA DE FAA (ÁCIDO FENILACÉTICO): PAGN (FENILACETILGLUTAMINA) MENOR A 1. DONDE SE AJUSTA LA DOSIFICACIÓN DE PROFÁRMACO DE PAAS (POR EJEMPLO. HPN-100, PBA) CON BASE EN LA MEDICIÓN DE FAA Y PAGN EN PLASMA Y CALCULAR LA RELACIÓN DE FAA: PAGN PARA ASÍ DETERMINAR SI LA CONVERSIÓN DE FAA A PAGN ES SATURADA.</p>
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261636256P | 2012-04-20 | 2012-04-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2017001375A1 true CL2017001375A1 (es) | 2018-01-05 |
Family
ID=49380684
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2014002807A CL2014002807A1 (es) | 2012-04-20 | 2014-10-17 | Metodos de monitoreo terapeutico de profarmacos de acido fenilacetico; metodos para tratar un tratornono de retencion de nitrogeno en un sujeto. |
| CL2017001375A CL2017001375A1 (es) | 2012-04-20 | 2017-05-30 | Métodos de monitoreo terapéutico de profármacos de ácido fenilacético. |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2014002807A CL2014002807A1 (es) | 2012-04-20 | 2014-10-17 | Metodos de monitoreo terapeutico de profarmacos de acido fenilacetico; metodos para tratar un tratornono de retencion de nitrogeno en un sujeto. |
Country Status (25)
| Country | Link |
|---|---|
| US (4) | US9561197B2 (es) |
| EP (2) | EP3222275B1 (es) |
| JP (3) | JP6234436B2 (es) |
| KR (2) | KR102264579B1 (es) |
| CN (3) | CN111991383A (es) |
| AU (3) | AU2012377389A1 (es) |
| BR (1) | BR112014026138A2 (es) |
| CL (2) | CL2014002807A1 (es) |
| CY (1) | CY1118838T1 (es) |
| DK (1) | DK2846791T3 (es) |
| EC (1) | ECSP14024561A (es) |
| ES (2) | ES2623470T3 (es) |
| HK (2) | HK1208380A1 (es) |
| HR (1) | HRP20170651T1 (es) |
| HU (1) | HUE032726T2 (es) |
| IL (2) | IL235127A (es) |
| LT (1) | LT2846791T (es) |
| MX (1) | MX365302B (es) |
| PL (1) | PL2846791T3 (es) |
| PT (1) | PT2846791T (es) |
| RS (1) | RS55870B1 (es) |
| SG (2) | SG10201608749UA (es) |
| SI (1) | SI2846791T1 (es) |
| WO (1) | WO2013158145A1 (es) |
| ZA (1) | ZA201407597B (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112014007357B1 (pt) | 2011-09-30 | 2022-12-06 | Immedica Pharma Ab | Método para determinar o ajuste da dosagem de um fármaco de varredura de nitrogênio |
| EP3222275B1 (en) | 2012-04-20 | 2020-06-24 | Immedica Pharma AB | Methods of therapeutic monitoring of phenylacetic acid prodrugs |
| LT2922576T (lt) * | 2012-11-21 | 2018-02-12 | Horizon Therapeutics, Llc | Azotą surišančių vaistų, skirtų kepenų encefalopatijos gydymui, skyrimo ir įvertinimo būdai |
| ES2746999T3 (es) | 2013-10-14 | 2020-03-09 | Immedica Pharma Ab | Métodos de tratamiento de trastornos del ciclo de la urea |
| US20170087113A1 (en) * | 2014-06-04 | 2017-03-30 | Horizon Therapeutics, Llc | Methods for treating urea cycle disorders to prevent hyperammonemic crises by controlling blood ammonia levels |
| US9914692B2 (en) | 2016-05-25 | 2018-03-13 | Horizon Therapeutics, Llc | Procedure for the preparation of 4-phenyl butyrate and uses thereof |
| US20190076383A1 (en) * | 2017-09-08 | 2019-03-14 | Horizon Therapeutics, Llc | Methods for treating urea cycle disorders |
| US10668040B2 (en) * | 2017-09-11 | 2020-06-02 | Horizon Therapeutics, Llc | Treatment of urea cycle disorders in neonates and infants |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4284647A (en) | 1980-03-31 | 1981-08-18 | The Johns Hopkins University | Process for waste nitrogen removal |
| US4457942A (en) | 1982-08-20 | 1984-07-03 | Brusilow Saul W | Process for waste nitrogen removal |
| US5635532A (en) | 1991-10-21 | 1997-06-03 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Compositions and methods for therapy and prevention of pathologies including cancer, AIDS and anemia |
| US5879657A (en) | 1993-03-30 | 1999-03-09 | The Dupont Merck Pharmaceutical Company | Radiolabeled platelet GPIIb/IIIa receptor antagonists as imaging agents for the diagnosis of thromboembolic disorders |
| EP0858441B1 (en) | 1995-02-07 | 2001-05-09 | Brusilow Enterprises, LLC | Triglycerides and ethyl esters of phenylalkanoic acid and phenylalkenoic acid useful in treatment of various disorders |
| US6219567B1 (en) | 1999-06-21 | 2001-04-17 | Cardiox Corporation | Monitoring of total ammoniacal concentration in blood |
| US20030195255A1 (en) | 2002-04-12 | 2003-10-16 | Summar Marshall L. | Method for treating hepatic encephalopathies |
| US20040229948A1 (en) | 2002-04-12 | 2004-11-18 | Summar Marshall L. | Method for preventing hepatic encephalopathic episodes |
| US20050273359A1 (en) | 2004-06-03 | 2005-12-08 | Young David E | System and method of evaluating preoperative medical care and determining recommended tests based on patient health history and medical condition and nature of surgical procedure |
| EP2319581B1 (en) | 2004-11-26 | 2015-02-25 | UCL Business PLC | Compositions comprising ornithine and phenylacetate or phenylbutyrate for treating hepatic encephalopathy |
| US20060135612A1 (en) | 2004-12-17 | 2006-06-22 | U.S. Department Of Veterans Affairs | Method of ameliorating or abrogating the effects of a neurodegenerative disorder, such as amyotrophic lateral sclerosis (ALS), by using a HDAC inhibiting agent |
| US20070004805A1 (en) | 2005-07-01 | 2007-01-04 | Navinta Llc | Process for preparation of liquid dosage form containing sodium 4-phenylbutyrate |
| WO2007059031A2 (en) | 2005-11-10 | 2007-05-24 | Massachusetts Institute Of Technology | Methods and compositions for raising levels and release of gamma aminobutyric acid |
| US8094521B2 (en) | 2007-02-28 | 2012-01-10 | Nightingale Products LLC | Caregiver personal alert device |
| GB2451259B (en) * | 2007-07-25 | 2011-07-20 | Gp Acoustics | Loudspeaker |
| EP2237684A2 (en) | 2008-01-08 | 2010-10-13 | Akthelia Pharmaceuticals | Agonists for antimicrobial peptide systems |
| US8642012B2 (en) | 2008-04-29 | 2014-02-04 | Hyperion Therapeutics, Inc. | Methods of treatment using ammonia-scavenging drugs |
| LT2330892T (lt) * | 2008-08-29 | 2016-11-25 | Horizon Therapeutics, Inc. | Gydymo būdai panaudojant vaistus - amoniako gaudykles |
| CA2735234A1 (en) * | 2008-08-29 | 2010-03-04 | Ucyclyd Pharma, Inc. | Dosing and monitoring patients on nitrogen-scavenging drugs |
| WO2011011781A1 (en) | 2009-07-24 | 2011-01-27 | Baylor College Of Medicine | Methods of modulation of branched chain acids and uses thereof |
| US20130224277A1 (en) | 2010-08-31 | 2013-08-29 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Porous polysaccharide scaffold comprising nano-hydroxyapatite and use for bone formation |
| BR112014007357B1 (pt) | 2011-09-30 | 2022-12-06 | Immedica Pharma Ab | Método para determinar o ajuste da dosagem de um fármaco de varredura de nitrogênio |
| EP3222275B1 (en) * | 2012-04-20 | 2020-06-24 | Immedica Pharma AB | Methods of therapeutic monitoring of phenylacetic acid prodrugs |
| LT2922576T (lt) | 2012-11-21 | 2018-02-12 | Horizon Therapeutics, Llc | Azotą surišančių vaistų, skirtų kepenų encefalopatijos gydymui, skyrimo ir įvertinimo būdai |
-
2012
- 2012-09-11 EP EP17154858.9A patent/EP3222275B1/en active Active
- 2012-09-11 BR BR112014026138A patent/BR112014026138A2/pt not_active Application Discontinuation
- 2012-09-11 WO PCT/US2012/054673 patent/WO2013158145A1/en active Application Filing
- 2012-09-11 HU HUE12874745A patent/HUE032726T2/en unknown
- 2012-09-11 US US13/610,580 patent/US9561197B2/en active Active
- 2012-09-11 CN CN202010449455.7A patent/CN111991383A/zh active Pending
- 2012-09-11 SI SI201230933A patent/SI2846791T1/sl unknown
- 2012-09-11 KR KR1020197029026A patent/KR102264579B1/ko active IP Right Grant
- 2012-09-11 AU AU2012377389A patent/AU2012377389A1/en not_active Abandoned
- 2012-09-11 EP EP12874745.8A patent/EP2846791B1/en active Active
- 2012-09-11 SG SG10201608749UA patent/SG10201608749UA/en unknown
- 2012-09-11 PT PT128747458T patent/PT2846791T/pt unknown
- 2012-09-11 RS RS20170421A patent/RS55870B1/sr unknown
- 2012-09-11 CN CN201280074143.6A patent/CN104540507A/zh active Pending
- 2012-09-11 CN CN202111191403.5A patent/CN113995743A/zh active Pending
- 2012-09-11 ES ES12874745.8T patent/ES2623470T3/es active Active
- 2012-09-11 KR KR1020147032114A patent/KR20150013170A/ko not_active IP Right Cessation
- 2012-09-11 DK DK12874745.8T patent/DK2846791T3/en active
- 2012-09-11 ES ES17154858T patent/ES2807951T3/es active Active
- 2012-09-11 PL PL12874745T patent/PL2846791T3/pl unknown
- 2012-09-11 LT LTEP12874745.8T patent/LT2846791T/lt unknown
- 2012-09-11 JP JP2015506953A patent/JP6234436B2/ja active Active
- 2012-09-11 MX MX2014012694A patent/MX365302B/es active IP Right Grant
- 2012-09-11 SG SG11201406745VA patent/SG11201406745VA/en unknown
-
2014
- 2014-10-17 CL CL2014002807A patent/CL2014002807A1/es unknown
- 2014-10-19 IL IL235127A patent/IL235127A/en active IP Right Grant
- 2014-10-20 ZA ZA2014/07597A patent/ZA201407597B/en unknown
- 2014-10-27 EC ECIEPI201424561A patent/ECSP14024561A/es unknown
-
2015
- 2015-09-18 HK HK15109202.8A patent/HK1208380A1/xx unknown
-
2017
- 2017-01-10 US US15/402,780 patent/US20170266143A1/en not_active Abandoned
- 2017-04-20 CY CY20171100449T patent/CY1118838T1/el unknown
- 2017-04-27 HR HRP20170651TT patent/HRP20170651T1/hr unknown
- 2017-05-30 CL CL2017001375A patent/CL2017001375A1/es unknown
- 2017-08-25 US US15/687,136 patent/US20180015058A1/en not_active Abandoned
- 2017-10-24 JP JP2017204831A patent/JP6637941B2/ja active Active
- 2017-11-26 IL IL255918A patent/IL255918B/en active IP Right Grant
-
2018
- 2018-01-09 AU AU2018200163A patent/AU2018200163B2/en active Active
- 2018-03-15 HK HK18103625.7A patent/HK1243959A1/zh unknown
- 2018-05-15 US US15/980,431 patent/US20180263938A1/en not_active Abandoned
-
2019
- 2019-03-15 AU AU2019201811A patent/AU2019201811B2/en active Active
- 2019-08-19 JP JP2019149843A patent/JP2019219413A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2017001375A1 (es) | Métodos de monitoreo terapéutico de profármacos de ácido fenilacético. | |
| CL2017003456A1 (es) | Metodos para tratar tumores de celulas epitelioides | |
| CY1121150T1 (el) | Νευροδραστικα 19-αλκοξυ-17-υποκατεστημενα στεροειδη, χρησιμα σε μεθοδους θεραπειας | |
| NZ720885A (en) | Rna transcription vector and uses thereof | |
| UY35590A (es) | Nuevos compuestos para el tratamiento del cáncer | |
| BR112013020513A2 (pt) | adoçante stevia altamente solúvel | |
| ECSP13012668A (es) | Ácidos 1-bencilcicloalquilcarboxílicos sustituidos y su uso | |
| CL2012000620A1 (es) | Formulaciones farmaceuticas de un anticuerpo anti cd-20; uso de la formulacion para tratar enfermedad o trastorno que pueda corregirse mediante tratamiento con anticuerpo anti-cd20. | |
| MX2020001262A (es) | Compuestos de platino a base de lipido y nanoparticulas. | |
| EA201691216A1 (ru) | Композиции линаклотида с замедленным высвобождением | |
| PH12015500252A1 (en) | Niclosamide for the treatment of solid tumors | |
| SG11201605159UA (en) | Processes to improve reactor stability for the preparation of ethylene-based polymers using asymmetrical polyenes | |
| BR112012032008A2 (pt) | anticorpos s100a4 e usos terapêuticos do mesmo | |
| MX2015014344A (es) | Terapia contra el cancer. | |
| CU24499B1 (es) | Proceso para preparar ésteres de ácido láctico y ácido 2-hidroxi-3-butenoico a partir de azúcares | |
| MX2013013891A (es) | Sistema y metodo de tratamiento de agua anti-incrustaciones. | |
| CL2015001085A1 (es) | Formulacion de liberación prolongada que comprende oprozomib y ademas uno o mas polimeros farmaceuticamente aceptables; metodo de preparacion de la formulacion; metodo para tratar cancer. | |
| BR112016008895A8 (pt) | métodos para formação de compostos homoalílicos pela reação de precursores de ciclopropilvinila com ácido de bronsted, e para formação de ambrox | |
| BR112015030431A2 (pt) | formulação de liberação modificada | |
| UY35771A (es) | Tienouracil-carboxamidas cíclicas y su uso | |
| BR112015013106A2 (pt) | uso de extrato de feno-grego para melhorar a libido feminina | |
| TN2017000174A1 (en) | Low dosage a2a antagonist for the treatment of adhd and parkinsons | |
| ES2403549R1 (es) | Co-cristales de agomelatina con formadores de co-cristales | |
| MX2020006075A (es) | Composiciones farmaceuticas de bendamustina. | |
| UA119441C2 (uk) | Посилювачі водорозчинності на основі глікогену |